01.06.26 -- Is 2026 The Year We End The 'Culture Wars' Between Sponsors And CDMOs?

This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more.

To ensure the success of gene therapy, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Maintaining the integrity of advanced therapies requires documented evidence of robust shipping processes. Qualification is essential for compliance and maintaining continuity across the supply chain.

Early, phase-appropriate CMC planning is critical for advanced therapy success. Proactively managing regulatory risks and applying Quality by Design principles secures a clear path to market.

Advanced therapy development today is less about big funding, more about frugality. Artificial intelligence unlocks a competitive advantage.

Short and long read sequencing offer complementary insights into AAV vector identity, integrity, and impurity profiles, helping developers improve safety, efficacy, and scalability of gene therapy products.

Enhance the success of your research and cell therapy programs by sourcing PBMCs with proven functional performance and donor-specific insights.

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

To overcome manufacturing bottlenecks and reduce the high cost of gene therapies, our ATLAS platform has identified novel factors that boost rAAV9 production over 30-fold.

Assimilate how genome engineering and iPSCs are being used to overcome the critical challenges of durability and host immune clearance in both clinical and preclinical settings for allogeneic cell therapies.

Observe how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that personalizes development, fosters engagement, and aligns training with real-world impact.

Viralgen’s Andy Holt at Meeting on the Mesa 2025 highlighted in-house plasmid manufacturing, expanded commercialization development, and cost reduction in gene therapy manufacturing.

Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.

Access customized end-to-end solutions. Expertise spans process development, drug substance manufacturing, and aseptic fill/finish, with broad technology for vaccines and cell and gene therapy.

Streamline cell and gene therapy logistics with an integrated platform that connects manufacturers with vital services, providing visibility and control for a more efficient and successful patient journey.

Embedded regulatory expertise strengthens compliance and accelerates timelines without adding headcount. Strategic insourcing delivers tailored support to reduce risk and boost efficiency.